SEC Company Response from NOVARTIS AG (NVS, NVSEF) (CIK 0001114448) (NVS) — Aug 15, 2011
NOVARTIS AG (NVS, NVSEF) (CIK 0001114448)
Date: Aug. 15, 2011 · CIK: 0001114448 · Accession: 0001104659-11-046781
AI Filing Summary & Sentiment
File numbers found in text: 001-15024
Referenced dates: June 30, 2011
Letter
Re: Novartis AG Form 20-F for Fiscal Year Ended December 31, 2010 Filed January 27, 2011 File No. 001-15024
Dear Mr. Rosenberg:
We are in receipt of your letter addressed to Jonathan Symonds, our Chief Financial Officer, dated July 29, 2011, which was in response to our letter dated June 30, 2011. As agreed in telephone calls between Barry Rosenfeld, of our affiliate Novartis Corporation, and Frank Wyman, Staff Accountant at SEC, our time to respond to your letter is extended through and including August 26, 2011. However, we anticipate that Comment 4 of your July 29 letter will be discussed during the scheduled August 29, 2011 conference call between SEC and Novartis.
Respectfully submitted,
Novartis AG
Show Raw Text
CORRESP 1 filename1.htm Novartis AG Postfach 4002 Basel Switzerland August 15, 2011 Mr. Jim B. Rosenberg Senior Assistant Chief Accountant US Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Re: Novartis AG Form 20-F for Fiscal Year Ended December 31, 2010 Filed January 27, 2011 File No. 001-15024 Dear Mr. Rosenberg: We are in receipt of your letter addressed to Jonathan Symonds, our Chief Financial Officer, dated July 29, 2011, which was in response to our letter dated June 30, 2011. As agreed in telephone calls between Barry Rosenfeld, of our affiliate Novartis Corporation, and Frank Wyman, Staff Accountant at SEC, our time to respond to your letter is extended through and including August 26, 2011. However, we anticipate that Comment 4 of your July 29 letter will be discussed during the scheduled August 29, 2011 conference call between SEC and Novartis. Respectfully submitted, Novartis AG /s/ JONATHAN SYMONDS /s/ THOMAS WERLEN Jonathan Symonds Thomas Werlen Chief Financial Officer General Counsel Novartis Group Novartis Group